kidney
Advertisement
At the NephCure Patient Summit, Montrez Lucas presented a session on how people with kidney disease can navigate insurance.
Dr. Purva Sharma educated patients with kidney disease about clinical trials in a NephCure 2025 Patient Summit session.
Social worker Janay Thompson shared mental health tips for patients with kidney disease at the NephCure 2025 Patient Summit.
Researchers assessed the burden of cardiovascular-kidney-metabolic (CKM) syndrome using NHANES 2001-2020 data.
Research explored kidney outcomes among young patients receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
A partnership will provide education to primary care clinicians to strengthen identification and treatment of kidney disease.
Research examined the efficacy and safety of lumasiran for primary hyperoxaluria type 1 in infants and toddlers.
A study explored the association between SCr/CYS ratio and adverse events associated with platinum-based cancer therapies.
Faith Lynch, president-elect of ANNA, discussed her upcoming term and challenges faced by nephrology nurses.
Oral iptacopan (Fabhalta) has become the first FDA-approved treatment for proteinuria in adults with C3 glomerulopathy.
A study assessed the role of and patterns of multimorbidity and their association with kidney function decline.
Ajay Singh discusses the state of rare kidney disease research.
Dietitian Lauren Budd Levy explains the importance of renal nutrition and related sessions at NKF SCM25.
LaVarne Burton of the American Kidney Fund opened Kidney Action Week 2025 with welcome remarks on March 3.
Listen to the discussion of Chapter 17 of Dr. Burton Rose's book, focused on simple and mixed acid-base disorders.
Travere will submit an application to the FDA requesting approval of sparsentan for focal segmental glomerulosclerosis.
How accurately and efficiently does artificial intelligence perform clinical prescreening compared with nephrologists?
The WRAPSODY stent may help restore circuit patency when stenosis or occlusion occurs within the AVG or AVF for hemodialysis.
Listen to part 2 of the discussion of Chapter 16 of Dr. Burton Rose's book, focused on edematous states.
A MAMS platform trial will examine use of antiproteinuric and immunomodulatory therapies in glomerular diseases.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.